Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.30 USD
Change Today +0.16 / 2.24%
Volume 490.9K
XNPT On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Key Developments

Xenoport, Inc. Reports New Expert Recommendations for the Prevention and Treatment of Augmentation in Patients Suffering from Restless Legs Syndrome

XenoPort, Inc. reported that new expert recommendations for the prevention and treatment of augmentation in patients suffering from restless legs syndrome (RLS) list gabapentin enacarbil as a first-line therapy with a lower risk of developing augmentation. In addition, gabapentin enacarbil is listed as an alternative treatment for the management of patients suffering from augmentation who were previously treated with dopaminergic medication. RLS augmentation is an insidious worsening of RLS symptoms that can occur after treatment of RLS with dopaminergic medication. The recommendations were created by the combined Task Force from the International RLS Study Group (IRLSSG), the European RLS Study Group (EURLSSG) and the RLS Foundation. HORIZANT® (gabapentin enacarbil) Extended-Release Tablets is the only non-dopaminergic medication and the only alpha-2-delta calcium-channel ligand class medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe primary RLS in adults.

Xenoport, Inc. to Present New Pooled Data Analyses on Horizant at the 2015 Sleep Annual Meeting

Xenoport, Inc. announced that pooled data analyses for HORIZANT (gabapentin enacarbil) Extended-Release Tablets, will be presented at the upcoming 29th Associated Professional Sleep Societies (APSS) annual SLEEP meeting in Seattle. The presentations include: Association Between Pain and Symptoms of Restless Legs Syndrome (RLS) in adults with moderate-to-severe. Primary RLS in a Combined Treatment Population: Pooled Analyses From 3 Randomized Controlled Trials. Poster #253, June 10, 205, Exhibit Hall 4AB. The Effect of Gabapentin Enacarbil on Pain Outcomes and Restless Legs Syndrome Symptoms in adults with moderate-to-severe primary RLS: Pooled Analyses From 3 Randomized, Controlled Trials. Poster #256, June 10, 2015, Exhibit Hall 4AB.

Xenoport, Inc. Approves Amendments to Amended and Restated Certificate of Incorporation

Xenoport, Inc. announced at the AGM held on May 19, 2015, it has approved amendments to the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock and approved amendments to the charter and company's amended and restated bylaws to eliminate the supermajority voting requirement for amendments to XenoPort's amended and restated bylaws.

Xenoport, Inc. Provides Sales Outlook for the Year 2015

Xenoport, Inc. provided sales outlook for the year 2015. For the period, the company expects net sales to be in the range of $39 million to $43 million.

Xenoport, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 10:00 AM

Xenoport, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $7.30 USD +0.16

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $6.45 USD +0.45
Alkermes PLC $70.02 USD +2.49
Bristol-Myers Squibb Co $65.64 USD +1.18
Skyepharma PLC 280.00 GBp +1.25
Valeant Pharmaceuticals International Inc C$335.61 CAD +4.75
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.